CSPC Pharmaceutical Group (HKG:1093) said the biologic license application for the ustekinumab injection has been accepted by China's National Medical Products Administration, a Tuesday bourse filing said.
The ustekinumab injection has been developed by CSPC Megalith Biopharmaceutical, a unit of the pharmaceutical company said.
The injection is a therapeutic biological product for the indication of plaque psoriasis in adults and children.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。